Thomas J. Lanza

Discovery of <i>N</i>-[(1<i>S</i>,2<i>S</i>)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a Novel, Acyclic Cannabinoid-1 Receptor Inverse Agonist for the Treatment of Obesity

Linus S. Lin, Thomas J. Lanza, James P. Jewell et al. · Journal of Medicinal Chemistry · 2006 · 122 citations · Full text

Cannabis Use, Molecular Pharmacology, Medicinal Chemistry +15

Antiobesity Efficacy of a Novel Cannabinoid-1 Receptor Inverse Agonist, N-[(1 S,2 S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), in Rodents

Tung M. Fong, Xiao-Ming Guan, Donald J. Marsh et al. · Journal of Pharmacology and Experimental Therapeutics · 2007 · 100 citations

Substituted 4,6-diaminoquinolines as inhibitors of C5a receptor binding

Thomas J. Lanza, Philippe L. Durette, Thomas E. Rollins et al. · Journal of Medicinal Chemistry · 1992 · 84 citations · Full text

Drug Target, Chemical Modification, Pharmacotherapy +16

Addressing the metabolic activation potential of new leads in drug discovery: a case study using ion trap mass spectrometry and tritium labeling techniques

Koppara Samuel, Wenji Yin, Ralph A. Stearns et al. · Journal of Mass Spectrometry · 2003 · 77 citations

Hit Identification, Metabolic Activation, Metabolomic Profiling +17

Inhibition of Stromelysin-1 (MMP-3) by P₁‘-Biphenylylethyl Carboxyalkyl Dipeptides

Craig K. Esser, Robert L. Bugianesi, Charles G. Caldwell et al. · Journal of Medicinal Chemistry · 1997 · 65 citations · Full text